Kennedy Capital Management Inc. purchased a new stake in shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 999,787 shares of the biopharmaceutical company’s stock, valued at approximately $5,099,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Broadfin Capital LLC lifted its stake in shares of Catalyst Pharmaceuticals by 22.0% in the fourth quarter. Broadfin Capital LLC now owns 6,268,298 shares of the biopharmaceutical company’s stock worth $12,035,000 after buying an additional 1,132,034 shares in the last quarter. BlackRock Inc. grew its stake in Catalyst Pharmaceuticals by 11.5% during the fourth quarter. BlackRock Inc. now owns 6,970,873 shares of the biopharmaceutical company’s stock valued at $13,384,000 after acquiring an additional 719,093 shares in the last quarter. EAM Global Investors LLC bought a new position in Catalyst Pharmaceuticals during the first quarter valued at $1,409,000. Parametric Portfolio Associates LLC bought a new position in Catalyst Pharmaceuticals during the first quarter valued at $952,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 4.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,458,151 shares of the biopharmaceutical company’s stock worth $16,852,000 after acquiring an additional 185,017 shares during the last quarter. Institutional investors and hedge funds own 59.79% of the company’s stock.
CPRX stock traded up $0.09 during mid-day trading on Wednesday, hitting $3.66. The stock had a trading volume of 78,214 shares, compared to its average volume of 2,099,663. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.08 and a quick ratio of 6.07. Catalyst Pharmaceuticals Inc has a 1-year low of $1.85 and a 1-year high of $6.16. The firm has a market cap of $363.08 million, a P/E ratio of -10.61 and a beta of 2.71.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Monday, May 13th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.12. The firm had revenue of $12.45 million during the quarter, compared to analyst estimates of $2.40 million. During the same period in the previous year, the company earned ($0.06) earnings per share. As a group, research analysts expect that Catalyst Pharmaceuticals Inc will post 0.11 EPS for the current year.
A number of research analysts have recently issued reports on CPRX shares. BidaskClub downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research report on Tuesday, May 21st. HC Wainwright set a $9.00 price target on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, May 14th. ValuEngine lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 8th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $10.00 target price on shares of Catalyst Pharmaceuticals in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $7.35.
In other news, CEO Patrick J. Mcenany bought 25,000 shares of the stock in a transaction dated Tuesday, June 11th. The stock was bought at an average cost of $3.23 per share, with a total value of $80,750.00. Following the purchase, the chief executive officer now owns 4,762,693 shares of the company’s stock, valued at $15,383,498.39. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 10.70% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Kennedy Capital Management Inc. Takes $5.10 Million Position in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2019/06/12/kennedy-capital-management-inc-takes-5-10-million-position-in-catalyst-pharmaceuticals-inc-nasdaqcprx.html.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Further Reading: Earnings Per Share
Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals Inc (NASDAQ:CPRX).
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.